secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001104659-24-053265
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Animal Health acquires Zoetis' medicated feed additive portfolio for $350M
--------------------------------------------------------------------------------

- $350M cash purchase; acquired portfolio generated ~$400M revenue in 2023 across 37 product lines.
- Six manufacturing sites (four US, one Italy, one China) and >300 Zoetis employees expected to transition.
- Deal expected to close H2 2024; Phibro to fund primarily with debt, targeting net leverage 3.5-4.0x at close.
- Phibro expects acquisition to boost EBITDA margin and be accretive to adjusted EPS.
- Combined pro forma sales ~$1.4B in last twelve months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000110465924053265/0001104659-24-053265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000110465924053265/tm2412927d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-053265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer